Logo.png
Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson’s Disease
March 29, 2022 17:00 ET | Vyant Bio, Inc.
Cherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug...
Logo.png
Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021
March 28, 2022 16:30 ET | Vyant Bio, Inc.
CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex...
Picture1
Vyant Bio Issues Letter to Shareholders
March 01, 2022 08:30 ET | Vyant Bio, Inc.
Cherry Hill, NJ, March 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological...
Logo.png
Vyant Bio to Present at the H.C. Wainwright Bioconnect Conference
January 10, 2022 08:00 ET | Vyant Bio, Inc.
Cherry Hill, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Logo.png
Vyant Bio to Present at The Benchmark Company Discovery One-on-One Investor Conference
November 29, 2021 09:15 ET | Vyant Bio, Inc.
Cherry Hill, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Logo.png
Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief Scientific Officer
October 26, 2021 08:00 ET | Vyant Bio, Inc.
Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company identifying small and large molecule...
Logo.png
MASORI THERAPEUTICS AND VYANT BIO, INC. ANNOUNCE NEW PARTNERSHIP
October 19, 2021 08:30 ET | Vyant Bio, Inc.
Engagement will combine MASORI’s global platforms and commercial experience in Japan to identify partnerships that leverage Vyant Bio’s advanced analytics and complex human-derived biology to drive...
Logo.png
MASORI THERAPEUTICS AND VYANT BIO, INC. ANNOUNCE NEW PARTNERSHIP
October 19, 2021 08:30 ET | Vyant Bio, Inc.
Engagement will combine MASORI’s global platforms and commercial experience in Japan to identify partnerships that leverage Vyant Bio’s advanced analytics and complex human-derived biology to drive...
Logo.png
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
August 19, 2021 09:27 ET | Vyant Bio, Inc.
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cureCollaboration creates opportunities to identify, validate, and...
Logo.png
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
August 16, 2021 16:01 ET | Vyant Bio, Inc.
Strategic Highlights Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States...